… studies of erlotinib (18) and panobinostat (13). The pharmacokinetic parameters for erlotinib
and panobinostat (14) seen in this study are … patients was comparable with prior studies that …

… -HDACi PS with erlotinib. In this study, we could show that the combination of erlotinib with
PS … , was enhanced by erlotinib, an effect of the TKI that has not been described previously. …

… romidepsin, belinostat and panobinostat, proved their efficacy … I study reported that an HDACi
was well tolerated by patients with … using cell lines, recent studies have proposed the use of …

… A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor,
combined with erlotinib in patients with advanced aerodigestive tract tumors. Clin Cancer …

… Comparable to the other HDACs, panobinostat leads to … Preclinical data suggests that
panobinostat has inhibitory activity … Here we review the current status of panobinostat and …

… patients in a phase I trial in combination with erlotinib. Disease stabilization could be
considered a clinically relevant result in patients affected by SCLC in second-line setting. In this …

… Enhanced combination effects were observed with erlotinib or EPZ011989–8 (Fig. 5A). … of
EGFR by panobinostat we explored further the combination of panobinostat to erlotinib at de-…

… Importantly, a recent study showed that panobinostat induced downregulation of EGFR in …
EGFR TKI erlotinib resulted in synergistic antiproliferative effects (19). An additional study also …

… In conclusion, this phase I study demonstrated that addition of panobinostat to carboplatin …
dose level of panobinostat tested in this trial. HDAC inhibitors, such as panobinostat, remain a …

… of first-line gefitinib and erlotinib over conventional cytotoxic chemotherapy, both in terms of
response rates and progression-free survival in patients with EGFR-mutant adenocarcinoma …